October 7th, 2008
Mothers who tested positive for breast cancer gene are now asking a tough question - should we test the kids?
Women with a faulty gene have a three to seven times greater risk of developing breast cancer and a higher risk of ovarian cancer. Men have more risk of prostate, pancreatic and other types of cancer.
With […]
By Grace Ibay -- 0 comments
April 12th, 2008
G&H’s INTERVIEW WITH NAVIGENICS
Navigenics approached Genetics and Health for an interview. With so much written about similar genomics companies such as 23andme, Knome, deCODE genetics, I was intrigued to learn more about this company. In particular, Navigenics appears to be the only company within this industry genre who provides a comprehensive wellness model – a […]
By Elaine -- 3 comments
April 9th, 2008
In this fourth in the series of articles originating from G&H’s exlusive interview with Navigenics’ Medical Director Dr Michael Nierenberg, we look at the whole issue of low penetrance versus high penetrance gene testing.
SNPs are known as ‘low penetrance genes’ where it will only sometimes produce the symptom or trait with which it has been associated […]
By Elaine -- 1 comment
November 29th, 2006
In response to the series of genetics articles published in The Jewish Standard last week, I asked Lisa Lee of DNA Direct to share her thoughts specifically on the article about direct-to-consumer genetic testing by Dr. Miryam Wahrman.
DNA Direct offers medical tests and provides information about medical guidelines for appropriateness of testing. For example, ACOG […]
By Hsien Hsien Lei, PhD -- 1 comment
March 22nd, 2006
Commercially available tests for breast cancer genes are missing 17 percent of mutations overall:
12% of BRCA1 and BRCA2 genes
5% of the cell cycle regulator CHEK2 gene
1% of the TP53 gene in families with Li-Fraumeni syndrome
More accurate genetic tests have been developed, but are not yet generally available in the United States. Women at high […]
By Hsien Hsien Lei, PhD -- 0 comments
December 14th, 2005
In the UK, genetic testing for the BRCA1 and BRCA2 breast/ovarian cancer genes is inefficient and incomplete.
Waiting time for appointments can be as long as nine months in two (11%) of the 19 regional genetics centers surveyed by CancerBACUP.
In one-third (32%) of genetics centres there is a more than six month wait. […]
By Hsien Hsien Lei, PhD -- 4 comments
Recent Comments